You just read:

Theravance Biopharma Announces Pricing of Public Offerings of 3,850,000 Ordinary Shares and $200 Million of 3.25% Convertible Senior Notes due 2023

News provided by

Theravance Biopharma, Inc.

Oct 28, 2016, 02:13 ET